Lindsay Janka

982 total citations · 1 hit paper
11 papers, 689 citations indexed

About

Lindsay Janka is a scholar working on Psychiatry and Mental health, Physiology and Pathology and Forensic Medicine. According to data from OpenAlex, Lindsay Janka has authored 11 papers receiving a total of 689 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Psychiatry and Mental health, 6 papers in Physiology and 5 papers in Pathology and Forensic Medicine. Recurrent topics in Lindsay Janka's work include Migraine and Headache Studies (6 papers), Trigeminal Neuralgia and Treatments (4 papers) and Sympathectomy and Hyperhidrosis Treatments (3 papers). Lindsay Janka is often cited by papers focused on Migraine and Headache Studies (6 papers), Trigeminal Neuralgia and Treatments (4 papers) and Sympathectomy and Hyperhidrosis Treatments (3 papers). Lindsay Janka collaborates with scholars based in United States, Germany and Israel. Lindsay Janka's co-authors include James Zangrilli, Jonathan Corren, Steven F. Weinstein, Margaret Garin, Xiaoping Ning, Joshua M. Cohen, Messoud Ashina, Maja Galić, Ronghua Yang and Melissa Grozinski‐Wolff and has published in prestigious journals such as The Lancet, Neurology and CHEST Journal.

In The Last Decade

Lindsay Janka

11 papers receiving 671 citations

Hit Papers

Fremanezumab versus placebo for migraine prevention in pa... 2019 2026 2021 2023 2019 50 100 150 200 250
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Fremanezumab versus placebo for migraine prevention in patients with documented failure to up to four migraine preventive medication classes (FOCUS): a randomised, double-blind, placebo-controlled, phase 3b trial
    2019 274 citations Michel D. Ferrari, Hans‐Christoph Diener et al. The Lancet profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Lindsay Janka United States 8 436 351 242 238 91 11 689
Figen Güney Türkiye 10 72 0.2× 51 0.1× 35 0.1× 27 0.1× 60 0.7× 23 467
Hsiu‐Wen Tsai United States 10 63 0.1× 14 0.0× 104 0.4× 96 0.4× 94 1.0× 21 325
A. M. Davies United Kingdom 9 80 0.2× 54 0.2× 138 0.6× 14 0.1× 125 1.4× 9 448
Jiachun Feng China 12 67 0.2× 193 0.5× 67 0.3× 97 0.4× 52 0.6× 30 529
Madeleine Murphy United Kingdom 11 84 0.2× 250 0.7× 38 0.2× 185 0.8× 36 0.4× 15 353
Neeraj Dubey United States 7 53 0.1× 211 0.6× 40 0.2× 333 1.4× 38 0.4× 8 616
Marina Quinlan United Kingdom 14 53 0.1× 36 0.1× 130 0.5× 12 0.1× 111 1.2× 23 481
Ufuk Utku Türkiye 15 21 0.0× 111 0.3× 106 0.4× 65 0.3× 49 0.5× 43 625
Iliyana Pacheva Bulgaria 10 23 0.1× 83 0.2× 32 0.1× 42 0.2× 31 0.3× 25 278
Paul D. Weyker United States 13 60 0.1× 33 0.1× 37 0.2× 88 0.4× 311 3.4× 25 494

Countries citing papers authored by Lindsay Janka

Since Specialization
Citations

This map shows the geographic impact of Lindsay Janka's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lindsay Janka with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lindsay Janka more than expected).

Fields of papers citing papers by Lindsay Janka

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lindsay Janka. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lindsay Janka. The network helps show where Lindsay Janka may publish in the future.

Co-authorship network of co-authors of Lindsay Janka

This figure shows the co-authorship network connecting the top 25 collaborators of Lindsay Janka. A scholar is included among the top collaborators of Lindsay Janka based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lindsay Janka. Lindsay Janka is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

11 of 11 papers shown
1.
McAllister, Peter, et al.. (2022). Impact of fremanezumab on disability outcomes in patients with episodic and chronic migraine: a pooled analysis of phase 3 studies. The Journal of Headache and Pain. 23(1). 112–112. 8 indexed citations
2.
3.
Nahas, Stephanie J., Steffen Naegel, Joshua M. Cohen, et al.. (2021). Efficacy and safety of fremanezumab in clinical trial participants aged ≥60 years with episodic or chronic migraine: pooled results from 3 randomized, double-blind, placebo-controlled phase 3 studies. The Journal of Headache and Pain. 22(1). 141–141. 15 indexed citations
4.
5.
6.
Ferrari, Michel D., Hans‐Christoph Diener, Xiaoping Ning, et al.. (2019). Fremanezumab versus placebo for migraine prevention in patients with documented failure to up to four migraine preventive medication classes (FOCUS): a randomised, double-blind, placebo-controlled, phase 3b trial. The Lancet. 394(10203). 1030–1040. 274 indexed citations breakdown →
7.
Silberstein, Stephen D., Peter McAllister, Xiaoping Ning, et al.. (2019). Safety and Tolerability of Fremanezumab for the Prevention of Migraine: A Pooled Analysis of Phases 2b and 3 Clinical Trials. Headache The Journal of Head and Face Pain. 59(6). 880–890. 38 indexed citations
8.
Corren, Jonathan, Steven F. Weinstein, Lindsay Janka, James Zangrilli, & Margaret Garin. (2016). Phase 3 Study of Reslizumab in Patients With Poorly Controlled Asthma. CHEST Journal. 150(4). 799–810. 299 indexed citations
9.
Corren, Jonathan, Steven F. Weinstein, Lindsay Janka, Christopher O’Brien, & James Zangrilli. (2014). A randomized phase 3 study of reslizumab efficacy in relation to blood eosinophil levels in patients with moderate to severe asthma. European Respiratory Journal. 44(Suppl 58). 4673–4673. 13 indexed citations
10.
11.
Nalamachu, Srinivas, et al.. (2011). Long-term dosing, safety, and tolerability of fentanyl buccal tablet in the management of noncancer-related breakthrough pain in opioid-tolerant patients. Current Medical Research and Opinion. 27(4). 751–760. 11 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Figen Güney Breakdown of academic impact, for papers by Hsiu‐Wen Tsai Breakdown of academic impact, for papers by A. M. Davies Breakdown of academic impact, for papers by Jiachun Feng Breakdown of academic impact, for papers by Madeleine Murphy Breakdown of academic impact, for papers by Neeraj Dubey Breakdown of academic impact, for papers by Marina Quinlan Breakdown of academic impact, for papers by Ufuk Utku Breakdown of academic impact, for papers by Iliyana Pacheva Breakdown of academic impact, for papers by Paul D. Weyker
Rankless by CCL
2026